(Q24194514)

1

0 references

Jonathan Craig

Jonathan C Craig

3

0 references

David Johnson

4

David W Johnson

0 references

Giovanni Strippoli

7

Giovanni FM Strippoli

0 references

Sankar Navaneethan

2

Sankar D Navaneethan

0 references

Jörgen Hegbrant

6

Cochrane Database of Systematic Reviews

Jorgen Hegbrant

0 references

publication date

31 May 2014

0 references

published in

0 references

cites work

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Differences in the treatment of coronary heart disease between countries as revealed in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of fluvastatin treatment on lipid profile, C-reactive protein trend, and renal function in dyslipidemic patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evalu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Physical activity levels in patients with chronic kidney disease entering the LORD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Dietary intake of patients with chronic kidney disease entering the LORD trial: adjusting for underreporting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Pravastatin and cardiovascular risk in moderate chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Estimation of treatment effect adjusting for treatment changes using the intensity score method: application to a large primary prevention study for coronary events (MEGA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Practical risk prediction tools for coronary heart disease in mild to moderate hypercholesterolemia in Japan: originated from the MEGA study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Socioeconomic status and telomere length: the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Parametric conditional frailty models for recurrent cardiovascular events in the lipid study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Monitoring cholesterol levels: measurement error or true change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The value of the electrocardiogram in risk assessment in primary prevention: experience from the West of Scotland Coronary Prevention Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The anatomy of a clinical trial. The West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Depression and cardiovascular morbidity and mortality: cause or consequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on cardiovascular events in people with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin in people with diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Biomarkers of inflammation and progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The value of N-terminal fragment of brain natriuretic peptide and tissue inhibitor of metalloproteinase-1 levels as predictors of cardiovascular outcome in the LIPID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Pravastatin Therapy and the Risk of Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of fosinopril and pravastatin on carotid intima-media thickness in subjects with increased albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Impact of weight change on albuminuria in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vasc

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of fosinopril treatment on serum C-reactive protein levels in patients with microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Safety and efficacy of atorvastatin in patients with severe renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Clinical insights from the Treating to New Targets trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering treat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Ant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Rosuvastatin in diabetic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Dose-dependent effect of rosuvastatin treatment on urinary protein excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of a multifactorial intervention on mortality in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Role of oxidized low-density lipoprotein in the atherosclerosis of uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of statins on inflammation in patients with acute and chronic coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Statins: effects beyond cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

HMG CoA reductase inhibitors (statins) for dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

HMG CoA reductase inhibitors (statins) for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of r

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Cholesterol-lowering therapy may retard the progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

A coronary primary prevention study of Scottish men aged 45-64 years: trial design. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Computerised record linkage: compared with traditional patient follow-up methods in clinical trials and illustrated in a prospective epidemiological study. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] S

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of pravastatin on blood pressure in people with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Long-term follow-up of the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Long-term follow-up of the West of Scotland Coronary Prevention Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Associated Effect of Hepatic Hydroxymethylglutaryl Coenzyme A Reductase + Angiotensin Converting Enzyme Inhibitors on the Progression of Renal Failure in Hypertensive Subjects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Quality of care in patients with chronic kidney disease is determined by hospital specific factors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction : a substudy of the Scandinavian simvastatin survival study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Predictors of Angiotensin-Converting Enzyme Inhibitor–Induced Reduction of Urinary Albumin Excretion in Nondiabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effects of Atorvastatin on Inflammatory and Fibrinolytic Parameters in Patients with Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007784.PUB2

7 January 2021

10.1002/14651858.CD007784.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

31638

31638

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference